Risk Factors of Subsequent Central Nervous System Tumors after Childhood and Adolescent Cancers: Findings from the French Childhood Cancer Survivor Study.
Adolescent
Adult
Cancer Survivors
/ statistics & numerical data
Case-Control Studies
Central Nervous System Neoplasms
/ epidemiology
Child
Cranial Irradiation
/ adverse effects
Dose-Response Relationship, Radiation
Female
France
Humans
Longitudinal Studies
Male
Neoplasms, Radiation-Induced
/ epidemiology
Neoplasms, Second Primary
/ epidemiology
Risk Factors
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
14
05
2020
revised:
31
07
2020
accepted:
30
09
2020
pubmed:
10
10
2020
medline:
27
11
2021
entrez:
9
10
2020
Statut:
ppublish
Résumé
Childhood or adolescent cancer survivors are at increased risks of subsequent primary neoplasms (SPN) of the central nervous system (CNS) after cranial irradiation. In a large multicentric cohort, we investigated clinical and therapeutic factors associated with the long-term risk of CNS SPN, and quantified the dose-response relationships. We selected all CNS SPN cases diagnosed up to 2016 among members of the French Childhood Cancer Survivor Study at least 5 years after first cancer diagnosis in 1946-2000. Four controls per case were randomly selected within the cohort and matched by sex, year of/age at first cancer diagnosis, and follow-up time. On the basis of medical and radiological reports, cumulative radiation doses received to the SPN or matched location were retrospectively estimated using mathematical phantoms. We computed conditional logistic regression models. Meningioma risk significantly increased with higher radiation doses [excess OR per Gy (EOR/Gy) = 1.377; The surveillance of patients with cranial irradiation should continue beyond 30 years after treatment. The identified risk factors may inform long-term surveillance strategies.
Sections du résumé
BACKGROUND
Childhood or adolescent cancer survivors are at increased risks of subsequent primary neoplasms (SPN) of the central nervous system (CNS) after cranial irradiation. In a large multicentric cohort, we investigated clinical and therapeutic factors associated with the long-term risk of CNS SPN, and quantified the dose-response relationships.
METHODS
We selected all CNS SPN cases diagnosed up to 2016 among members of the French Childhood Cancer Survivor Study at least 5 years after first cancer diagnosis in 1946-2000. Four controls per case were randomly selected within the cohort and matched by sex, year of/age at first cancer diagnosis, and follow-up time. On the basis of medical and radiological reports, cumulative radiation doses received to the SPN or matched location were retrospectively estimated using mathematical phantoms. We computed conditional logistic regression models.
RESULTS
Meningioma risk significantly increased with higher radiation doses [excess OR per Gy (EOR/Gy) = 1.377;
CONCLUSIONS
The surveillance of patients with cranial irradiation should continue beyond 30 years after treatment.
IMPACT
The identified risk factors may inform long-term surveillance strategies.
Identifiants
pubmed: 33033142
pii: 1055-9965.EPI-20-0735
doi: 10.1158/1055-9965.EPI-20-0735
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
133-141Informations de copyright
©2020 American Association for Cancer Research.
Références
Steliarova-Foucher E, Colombet M, Ries LAG, Moreno F, Dolya A, Bray F, et al. International incidence of childhood cancer, 2001–10: a population-based registry study. Lancet Oncol. 2017;18:719–31.
Hewitt M, Weiner SL, Simone JV. Childhood cancer survivorship: improving care and quality of life. 2003.
Armstrong GT, Kawashima T, Leisenring W, Stratton K, Stovall M, Hudson MM, et al. Aging and risk of severe, disabling, life-threatening, and fatal events in the Childhood Cancer Survivor Study. J Clin Oncol. 2014;32:1218–27.
Taylor AJ, Little MP, Winter DL, Sugden E, Ellison DW, Stiller CA, et al. Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study. J Clin Oncol. 2010;28:5287–93.
Neglia JP, Robison LL, Stovall M, Liu Y, Packer RJ, Hammond S, et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2006;98:1528–37.
Taylor AJ, Frobisher C, Ellison DW, Reulen RC, Winter DL, Taylor RE, et al. Survival after second primary neoplasms of the brain or spinal cord in survivors of childhood cancer: results from the British Childhood Cancer Survivor Study. J Clin Oncol. 2009;27:5781–7.
Bowers DC, Nathan PC, Constine L, Woodman C, Bhatia S, Keller K, et al. Subsequent neoplasms of the CNS among survivors of childhood cancer: a systematic review. Lancet Oncol. 2013;14:e321–8.
Kok JL, Teepen JC, van Leeuwen FE, Tissing WJE, Neggers S, van der Pal HJ, et al. Risk of benign meningioma after childhood cancer in the DCOG-LATER cohort: contributions of radiation dose, exposed cranial volume, and age. Neuro Oncol. 2019;21:392–403.
Little MP, de Vathaire F, Shamsaldin A, Oberlin O, Campbell S, Grimaud E, et al. Risks of brain tumour following treatment for cancer in childhood: modification by genetic factors, radiotherapy and chemotherapy. Int J Cancer. 1998;78:269–75.
Friedman DL, Whitton J, Leisenring W, Mertens AC, Hammond S, Stovall M, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2010;102:1083–95.
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20.
Veres C, Allodji RS, Llanas D, Vu Bezin J, Chavaudra J, Mege JP, et al. Retrospective reconstructions of active bone marrow dose-volume histograms. Int J Radiat Oncol Biol Phys. 2014;90:1216–24.
Preston D, Lubin J, Pierce D, McConney M, Shilnikova N. Epicure risk regression and person-year computation software: command summary and user guide. 2015.
Vinchon M, Leblond P, Caron S, Delestret I, Baroncini M, Coche B. Radiation-induced tumors in children irradiated for brain tumor: a longitudinal study. Childs Nerv Syst. 2011;27:445–53.
Brenner AV, Sugiyama H, Preston DL, Sakata R, French B, Sadakane A, et al. Radiation risk of central nervous system tumors in the Life Span Study of atomic bomb survivors, 1958–2009. Eur J Epidemiol. 2020;35:591–600.
Sadetzki S, Chetrit A, Freedman L, Stovall M, Modan B, Novikov I. Long-term follow-up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis. Radiat Res. 2005;163:424–32.
Pearce MS, Salotti JA, Little MP, McHugh K, Lee C, Kim KP, et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet. 2012;380:499–505.
Berrington de Gonzalez A, Salotti JA, McHugh K, Little MP, Harbron RW, Lee C, et al. Relationship between paediatric CT scans and subsequent risk of leukaemia and brain tumours: assessment of the impact of underlying conditions. Br J Cancer. 2016;114:388–94.
Relling MV, Rubnitz JE, Rivera GK, Boyett JM, Hancock ML, Felix CA, et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet. 1999;354:34–9.
Clayton PE, Banerjee I, Murray PG, Renehan AG. Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat Rev Endocrinol. 2011;7:11–24.
Patterson BC, Chen Y, Sklar CA, Neglia J, Yasui Y, Mertens A, et al. Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2014;99:2030–7.
Swerdlow AJ, Cooke R, Beckers D, Borgstrom B, Butler G, Carel JC, et al. Cancer risks in patients treated with growth hormone in childhood: the SAGhE European Cohort Study. J Clin Endocrinol Metab. 2017;102:1661–72.
Swerdlow AJ, Cooke R, Beckers D, Butler G, Carel JC, Cianfarani S, et al. Risk of meningioma in European patients treated with growth hormone in childhood: results from the SAGhE Cohort. J Clin Endocrinol Metab. 2019;104:658–64.
Vu Bezin J, Allodji RS, Mege JP, Beldjoudi G, Saunier F, Chavaudra J, et al. A review of uncertainties in radiotherapy dose reconstruction and their impacts on dose-response relationships. J Radiol Prot. 2017;37:R1–R18.